Solid Biosciences Inc. (SLDB)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Ally Bridge Group NY LLC Has $3.39 Million Stock Position in Solid Biosciences Inc. $SLDB
Ally Bridge Group NY LLC cut its stake in shares of Solid Biosciences Inc. (NASDAQ: SLDB) by 24.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 549,182 shares of the company's stock after selling 174,818 shares during
Solid Biosciences Inc. (SLDB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Solid Biosciences Inc. (SLDB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start
Solid Biosciences retains a "Strong Buy" rating, driven by robust interim data for SGT-003 in pediatric Duchenne Muscular Dystrophy [DMD]. The company demonstrated 60% mean microdystrophin expression at Day 90 in its phase 1/2 INSPIRE DUCHENNE trial, with safety confirmed in 40 patients. A $240 million private placement in March 2026 extends the cash runway, supporting key milestones through 2027.
Solid Biosciences Inc. (SLDB) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Solid Biosciences Inc. (SLDB) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones
Solid Biosciences maintains a 'Strong Buy' rating, driven by positive FDA alignment on the phase 3 IMPACT DUCHENNE trial for SGT-003 in DMD. The company expects key catalysts in mid-2026: potential FDA Accelerated Approval discussions for SGT-003 and additional data from the phase 1/2 INSPIRE DUCHENNE study. SLDB's capsid design targets improved muscle function and reduced toxicity, with phase 1/2 data showing 58% mean microdystrophin expression and favorable safety.
Solid Biosciences Inc. (SLDB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Solid Biosciences Inc. (SLDB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)
Solid Biosciences is approaching key catalysts in DMD gene therapy, with SGT-003 showing promising early safety and efficacy signals. The evolving DMD landscape, especially safety concerns with competitors, enhances the appeal of Solid's muscle-tropic vector and unique R16/R17 domains. Despite significant dilution and ongoing losses, Solid's strong cash position supports its pipeline through 2027, justifying an upgrade from Hold to Buy.
Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space
Solid Biosciences is repositioning itself in a scrutinized space with promising early-stage trial results for its lead candidate, SGT-003. Recent events involving Sarepta Therapeutics have unfairly impacted Solid's stock price, creating a potential recovery opportunity if Sarepta clarifies the isolated nature of the patient's death. Solid's pipeline includes SGT-003 for DMD, SGT-212 for Friedreich's ataxia, and SGT-501 for CPVT, with promising early data and no serious adverse effects.
Can Solid Biosciences Challenge Sarepta in the DMD Market?
When it comes to treating Duchenne muscular dystrophy (DMD), big news recently surfaced. DMD is a muscle disease.
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 198.2% in Solid Biosciences (SLDB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SLDB Stock Rallies 60% in a Month: Here's What You Should Know
Solid Biosciences stock soars 60% in a month after the company announced positive initial data from its phase I/II DMD study of SGT-003.
